Oculis and European Biotech Acquisition Corp. Announce Business Combination Agreement
London – October 25, 2022 – Cooley served as US legal counsel to Oculis in its business combination with European Biotech Acquisition Corp. Partners Michal Berkner, Div Gupta, Ryan Sansom and Aaron Pomeroy led the Cooley team.
The new company will be known as Oculis Holding, and it is expected to have a post-transaction enterprise value of approximately $220 million and a cash balance exceeding $200 million, including a gross private investment in public equity (PIPE) and private investment of close to $80 million.
Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address medical needs with breakthrough innovations. Headquartered in Lausanne, Switzerland, with operations in Europe, the US and China, Oculis is led by an experienced management team that has an extensive track record and is supported by leading international healthcare investors.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of 3,300.